Table 1.
Clinical and demographic features of PD patients at inclusion
| N° patient | Sex/Age (yrs) | Disease duration (yrs) | Time since STN-DBS (months) | Falls/FOG duration (months) | UPDRS part II: falls/FOG | UPDRS part III (/108) | Hoehn&Yahr stage (/5) | FOG-Q (/64) | ABC scale (%) | LEED (mg/day) |
|---|---|---|---|---|---|---|---|---|---|---|
| 01 | M/58 | 13 | 26 | 20 | 2/3 | 21 | 3 | 32 | 70 | 700 |
| 02 | F/68 | 21 | 52 | 14 | 3/2 | 27 | 4 | 32 | 39 | 700 |
| 03 | M/62 | 15 | 60 | 30 | 2/3 | 20 | 3 | 22 | 51 | 350 |
| 04 | F/69 | 16 | 93 | 80 | 2/2 | 13 | 3 | 27 | 46 | 300 |
| 05 | M/70 | 17 | 18 | 13 | 2/3 | 15 | 3 | 21 | 69 | 600 |
| 06 | M/69 | 32 | 183 | 159 | 4/4 | 32 | 4 | 30 | 50 | 200 |
| 07 | F/69 | 20 | 34 | 26 | 2/3 | 13 | 3 | 20 | 22 | 600 |
| 08 | F/61 | 13 | 37 | 25 | 2/2 | 14 | 3 | 17 | 64 | 400 |
| 09 | F/53 | 23 | 140 | 65 | 2/3 | 15 | 3 | 30 | 31 | 300 |
| 10 | M/61 | 11 | 20 | 18 | 2/3 | 33 | 4 | 28 | 72 | 700 |
| Mean (SD) | 64.0 (5.8) | 18.1 (6.2) | 66.3 (55.8) | 45.0 (45.9) | 2.3 (0.7)/2.8 (0.6) | 20.3 (7.8) | 3.3 (0.5) | 25.9 (5.4) | 51.4 (17.3) | 485 (205) |
ABC activity balance confidence, FOG-Q freezing of gait questionnaire, LEED levodopa-equivalent dosage, STN-DBS subthalamic deep brain stimulation, UPDRS unified Parkinson’s disease rating scale